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Both urokinase-like plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor (PAI-1), as well as uPA–PAI-1
complexes, have been identified as important prognostic factors in breast cancer. We have recently reported that the latter are
identifiable inside breast cancer cells by means of immunohistochemistry. Using this technique, we have studied a series of 212 early
(pT1) unifocal breast cancers and have correlated the expression of uPA–PAI-1 complexes, together with other clinical and
biological features (histologic variety, histologic and nuclear grade, hormone receptors, Ki67 labelling index, c-erb-B2-, p53- and
CD44std-expression) with or without the occurrence of axillary node invasion. In a logistic regression model, looking for associations
with axillary metastasis, we found a statistically significant interaction between the presence of uPA–PAI-1 complexes and
progesterone receptor positivity (P¼0.04). A final model showed that the presence of uPA–PAI-1 complexes was a determinant
factor for axillary metastasis among women carrying tumours expressing progesterone receptors. In these cases, the presence of
uPA–PAI-1 complexes carried with it a nearly 14-fold risk of axillary node invasion (P¼0.009). These results may indicate that small,
hormone-receptor-positive breast cancers (with a theoretical good prognosis) may carry an elevated risk of nodal involvement if
accumulation of uPA–PAI-1 complexes is shown inside their tumour cells by means of immunohistochemistry.
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Among the mechanisms involved in tumour invasion and
metastasis, basement membrane and, more generally, extracellular
matrix degradation is likely to play a major role. Several
physiologically active enzymes are used for this purpose by the
tumour cells. The plasminogen activation system, necessary for
clot degradation, and also involved in wound healing and
inflammation, is one of such mechanisms incorporated by tumour
cells for developing the metastatic phenotype (Andreasen et al,
1997). Two natural plasminogen activators are known, tissue-type
plasminogen activator (tPA) and urokinase-like plasminogen
activator (uPA). Of them, it is the latter, uPA, which plays the
most important role in basement membrane, and, more generally,
peritumoral matrix degradation. The inactive form of uPA (pro-
uPA) is secreted mainly by stromal cells (and to a much lesser
extent also by tumour cells), and is activated by binding to its cell-
surface receptor (uPAR). Active receptor-bound uPA in its turn
activates the passage of plasminogen to plasmin, a strong
proteolytic enzyme, which furthermore activates metalloprotei-
nases, thus creating a localised microenvironment of matrix
degradation, through which migration of tumour cells is
facilitated. In the long run, however, such an unspecific proteolytic
effect in the immediate surrounding of the tumour cell would be
dangerous for the tumour cell itself, so that the whole process is
held in control by a negative feedback loop, mediated by specific
inhibitors of uPA, called plasminogen activator inhibitors (PAI).
Two of them are known (PAI-1 and PAI-2), although it seems that,
in practice, it is mainly PAI-1 that comes into play in solid
tumours. Only the active form of uPAR-bound uPA interacts with
PAI-1, forming stable uPA–PAI complexes that are internalised
(Olson et al, 1992). We have recently been able to visualise this
step of the chain by means of immunohistochemistry, using an
antibody that selectively reacts with uPA–PAI-1 complexes
(Schneider et al, 2000). In the same study, we also found that
hormones seem to play a role in the whole process, because the
accumulation of uPA–PAI complexes inside the tumour cells was
significantly associated with the expression of oestrogen and
progesterone receptors by them.
Both uPA and its inhibitor PAI-1, as well as uPA–PAI-1
complexes, have been identified as important prognostic factors in
breast cancer. Schmitt et al (1991) were the first to report that PAI-
1 expression is associated with a significantly worse outcome in
breast cancer, and these initial findings were corroborated by the
same group later, after long-term follow-up (Harbeck et al, 1999),
as well as by Foekens et al (2000). Similar results were obtained for
uPA by Grndahl-Hansen et al (1993). Ja ¨nicke et al (2001) found
the combination of uPA/PAI-1 to have a negative prognostic
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complexes, finally, which is formed as a result of the interaction
between uPA and its inhibitor PAI-1, has been associated with a
better prognosis by Pedersen et al (2000), but also with a worse
prognosis by Sten-Lindner et al (2001).
Taking into consideration the decisive role of the uPA–PAI
system in the metastatic process, we have carried out the present
study in order to verify if the presence of uPA–PAI-1 complexes,
together with other biological features of the primary tumour, aids
in predicting axillary nodal metastasis in early breast cancer at the
time of surgery.
MATERIALS AND METHODS
For this study, only unifocal invasive tumours with a pathologi-
cally verified diameter of 2cm or less (pT1) were considered.
Between January 1993 and December 2000, 212 patients harbour-
ing tumours showing these features were operated upon at our
institution. Of them, the vast majority were infiltrating ductal
carcinomas (178; 84%), followed by lobular infiltrating carcinomas
(16; 7.5%), pure tubular carcinomas (10; 4.7%) and other, less
frequent histologic varieties (8; 3.8%). Substaging according to size
was as follows: pT1a (0.1–0.5cm); nine cases (4.2%); pT1b (0.6–
1.0cm); 51 cases (24.1%); pT1c (1.1–2.0cm), 152 cases (71.7%). A
complete axillary dissection was carried out in every patient. More
than 10 axillary nodes were removed in all of them (range: 18–52).
Axillary metastasis was present in 54 out of the 212 patients of the
study (25.5%). None of the patients with pT1a tumours had
invaded nodes vs 9/51 of those carrying pT1b tumours (17.6%),
and 45/152 (29.6%) of patients with pT1c tumours.
Besides histology and tumour size, the other variables of the
study taken into consideration for predicting axillary node
invasion were as follows: histologic and nuclear grade (33
unknown), oestrogen and progesterone receptor expression
(three unknown), the Ki67 labelling index (three unknown), c-
erb-B2 expression (26 unknown), mutant p53 expression (23
unknown), CD44std expression (30 unknown), and finally uPA –
PAI-1 complex accumulation inside the tumour cells (23
unknown).
Immunohistochemistry
The immunohistochemical technique employed has been exten-
sively described elsewhere (Schneider et al, 1999, 2000). Briefly,
5-mm paraffin sections were mounted on poly L-lysine-coated
slides for heat-induced epitope retrieval (‘HIER’ technique) in
citrate buffer. We used the same, commercially available
streptavidin –
biotin – peroxidase kit (Histostain-SP, Zymed, San Francisco,
CA, USA) throughout the whole procedure, to ensure uniformity of
results. The antibodies employed were as follows: NCL-CB11 (c-
erb-B2), NCL-ER-6F11 (ER), NCL-p53-D07 (p53), all from
Novocastra Laboratories, Newcastle, UK; prediluted MIB1 (Ki67)
and PR-2C5 (PR) from Zymed, San Francisco, CA, USA; BMS113
(CD44std) from Boehringer Ingelheim, Germany; AB775 (uPA–
PAI-1 complexes) from Chemicon International, Temecula, CA,
USA (which is the same as the former antibody BMS4139 from
Boehringer Ingelheim, Germany). This antibody was developed
and characterised by Cederholm-Williams et al (1985) and shown
by reverse zymography to selectively recognise uPA–PAI-1
Figure 1 Immunohistochemical detection of uPA-PAI-1 complexes in breast cancer. Streptavidin-biotin peroxidase X 250. (A) Strong reaction in o10%
tumour cells. Very weak reaction in the rest of tumour cells. No reaction in stromal cells. (B) Negative control of A). (C) Strong, granular reaction in most
tumour cells. No stromal reaction. (D) Negative control of C).
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British Journal of Cancer (2003) 88(1), 96–101 & 2003 Cancer Research UKcomplexes. We recently demonstrated by means of immuno-
histochemistry that it reacts with uPA–PAI-1 complexes (Schnei-
der et al, 2000), and that the reaction is located intracellularly, as
predicted by means of biochemical methods by Olson et al (1992).
Negative controls were carried out in parallel by omitting the first
antibody (Figure 1). The incubation time was 1h at room
temperature in a humid chamber for all antibodies, which, apart
from the prediluted MIB1-Ki67 solution, which was directly used
as supplied, were employed at following dilutions: NCL-CB11 (c-
erb-B2), 1:40; NCL-ER-6F11 (ER), 1:100; NCL-p53-D07, 1:100;
BMS113 (CD44std), 1:100; AB775 (uPA–PAI-1 complexes),
1:1.000. The evaluation of nuclear staining patterns (ER, PR,
Ki67 and p53) was straightforward, since tumours positive for ER,
PR or p53 always showed specific staining in more than 10% of
tumour cells. The Ki67 labelling index was expressed as the
percentage of reactive tumour cells. For the evaluation of CD44std
and uPA–PAI-1 staining, finally, we adopted the scoring system
used by us in the past (Schneider et al, 1999, 2000), which takes
into account both the staining intensity and the proportion of
reactive tumour cells, and gives a final score ranging between 0 and
6 (6 corresponding to the highest expressors, showing intense
staining in more than 20% of the tumour cells). The slides were
evaluated twice in a blinded fashion, with an interval of 1 month,
after reshuffling. In those cases where a discrepancy arose between
the first and the second evaluation (less than 10% of the cases), a
consensus was reached.
Statistics
The strength of the association between uPA–PAI-1 complex
expression and the rest of variables with the presence of axillary
node involvement was assessed computing the corresponding odds
ratios using unconditional logistic regression. In a second step, the
possible interaction between uPA–PAI-1 complexes and other
variables was explored through a stratified analysis and the
statistical significance was computed via logistic regression
including the corresponding interaction term. Given the different
results obtained according to the presence or absence of
progesterone receptors, and that the effect of uPA–PAI-1
complexes seemed to be restricted to tumours with progesterone
receptors, the multivariate model was fitted taking this interaction
into account. Furthermore, the multivariate analysis was also built
in independently in women with and without progesterone
receptors. The statistical analysis was carried out using the STATA
statistical package (Stata Corporation, TX, USA).
RESULTS
Univariate and bivariate analysis
All clinical and biological tumour variables potentially associated
with axillary node invasion were individually tested in a univariate
model (Table 1). Only histologic grade (P¼0.013), high prolifera-
tion (Ki67410%; P¼0.008) and absence of CD44std expression
(Po0.001) emerged as significant predictors of axillary metastasis,
in agreement with the results previously published by us
(Schneider et al, 1999). In fact, the present series of early breast
cancers is an extension of that previously published one, and these
results are now confirmatory of the ones obtained in that
preliminary study. Any degree of uPA–PAI-1 complex accumula-
tion inside the tumour cells showed a trend towards a significant
association with nodal metastasis. Thus, in the further analyses
carried out, tumours were termed uPA–PAI-1-positive or
-negative, regardless of the number of staining cells, or the
intensity of the reaction. Small tumour size and tubular histology,
conversely, showed a trend towards statistically significant absence
of invaded nodes (see Table 2).
Table 3 depicts the stratified analysis of the effect of uPA–PAI-1
complexes by categories of the other variables. The statistical
significance of the interaction between uPA–PAI and that
particular variable is presented in the last column. The most
interesting finding in this analysis was the interaction observed
between uPA–PAI-1 and oestrogen and progesterone receptor
positivity (ER+PR+). The prognostic effect of uPA–PAI-1
complexes seemed to be restricted to those cases with hormonal
receptors. All tumours expressing progesterone receptors did also
express oestrogen receptors. The contrary was however not always
the case. When testing these oestrogen-receptor-positive, proges-
Table 1 Prognostic factors related to axillary lymph node inasion in early
(T1) breast cancer: Univariate analysis
Number of
women
No. of women
with positive
nodes (%) OR 95% CI P-value
Histologic type
Ductal 178 47 (26%) 1
Lobular 16 5 (31%) 1.26 0.42–3.84 0.676
Tubular 10 0 ( 0%) 0.00 0.00–1.09 0.069
Rest of types 8 2 (25%) 0.93 0.18–4.76 0.930
Tumour size
>1cm 152 45 (30%) 1
1–0.6cm 51 9 (18%) 0.51 0.23–1.13 0.098
p0.5cm 9 0 ( 0%) 0.00 0.00–1.04 0.063
uPA–PAI-1
0 55 10 (18%) 1
1–4 48 15 (31%) 2.04 0.82–5.12 0.126
5–6 86 25 (29%) 1.84 0.81–4.22 0.148
Unknown 23 4 (17%) 0.80 0.26–3.40 0.934
Hormone receptors
ER PR  61 14 (23%) 1
ER+PR  24 7 (29%) 1.38 0.48–4.00 0.551
ER+PR+ 124 33 (27%) 1.21 0.59–2.49 0.591
Unknown 3 0 ( 0%) 0.00 0.00–4.68 1.000
Nuclear grade
1 and 2 122 32 (26%) 1
3 57 16 (28%) 1.10 0.54–2.22 0.796
Unknown 33 6 (18%) 0.63 0.24–1.65 0.343
Histologic grade
1 and 2 139 31 (22%) 1
3 40 17 (43%) 2.58 1.22–5.41 0.013
Unknown 33 6 (18%) 0.77 0.29–2.04 0.605
Ki67
p10% 89 16 (18%) 1
>10% 99 35 (35%) 2.50 1.26–4.93 0.008
Unknown 24 3 (13%) 0.65 0.17–2.45 0.527
c-erb-B2
Negative 159 43 (27%) 1
Positive 27 7 (26%) 0.94 0.37–2.39 0.904
Unknown 26 4 (15%) 0.49 0.16–1.51 0.213
p53
Negative 154 41 (27%) 1
Positive 35 10 (29%) 1.10 0.49–2.49 0.815
Unknown 23 3 (13%) 0.41 0.13–1.46 0.171
CD44
3–6 110 18 (16%) 1
1–2 22 5 (23%) 1.50 0.49–4.60 0.475
Negative 50 25 (50%) 5.11 2.41–10.8 o0.001
Unknown 30 6 (20%) 1.28 0.45–3.57 0.640
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British Journal of Cancer (2003) 88(1), 96–101 & 2003 Cancer Research UKTable 2 Stratified analysis of uPA–PAI categories by the rest of the predictors. Statistical significance of the interaction between uPA–PAI complexes and
the other variables
Number of
women
Women with
positive nodes (%) OR
a 95% CI
a
P-value of the
estimator
a
P-value of the
interaction
b
Histologic type
Ductal
uPA negative 39 7 (18%) 1.00
uPA positive 122 38 (31%) 2.07 0.84–5.10 0.115
Other
uPA negative 16 3 (19%) 1.00
uPA positive 12 2 (17%) 0.87 0.12–6.21 0.887 0.419
Tumour size
>1cm
uPA negative 43 9 (21%) 1.00
uPA positive 93 32 (34%) 1.98 0.85–4.64 0.115
p1cm
uPA negative 12 1 ( 8%) 1.00
uPA positive 41 8 (20%) 2.67 0.30–23.8 0.380 0.804
Receptors
ER PR 
uPA negative 22 6 (27%) 1.00
uPA positive 36 8 (22%) 0.76 0.22–2.59 0.663
ER+PR 
uPA negative 3 1 (33%) 1.00
uPA positive 16 4 (25%) 0.67 0.05–9.47 0.765 0.929
ER+PR+
uPA negative 30 3 (10%) 1.00
uPA positive 80 28 (35%) 4.85 1.35–17.4 0.016 0.040
Nuclear grade
1–2
uPA negative 20 2 (10%) 1.00
uPA positive 88 28 (32%) 4.20 0.91–19.4 0.066
3
uPA negative 19 5 (26%) 1.00
uPA positive 35 11 (31%) 1.28 0.37–4.46 0.695 0.239
Histologic grade
1–2
uPA negative 31 3 (10%) 1.00
uPA positive 94 26 (28%) 3.57 1.00–12.8 0.050
3
uPA negative 8 4 (50%) 1.00
uPA positive 29 13 (45%) 0.81 0.17–3.89 0.795 0.151
Ki67
p10%
uPA negative 25 3 (12%) 1.00
uPA positive 52 10 (19%) 1.75 0.44–7.01 0.432
>10%
uPA negative 25 7 (28%) 1.00
uPA positive 66 27 (41%) 1.78 0.65–4.85 0.259 0.982
c-erb-2
Negative
uPA negative 42 8 (19%) 1.00
uPA positive 97 31 (32%) 2.00 0.83–4.82 0.124
Positive
uPA negative 7 2 (29%) 1.00
uPA positive 20 5 (25%) 0.83 0.12–5.72 0.853 0.419
p53
Negative
uPA negative 41 8 (20%) 1.00 0.78–4.62
uPA positive 92 29 (32%) 1.90 0.157
Positive
uPA negative 8 2 (25%) 1.00
uPA positive 27 8 (30%) 1.26 0.21–7.65 0.799 0.691
CD44
Positive
uPA negative 36 4 (11%) 1.00 0.49–4.60 0.242
uPA positive 90 18 (20%) 2.00
Negative
uPA negative 18 6 (33%) 1.00
uPA positive 32 19 (59%) 2.92 0.87–9.78 0.082 0.657
aEstimators and P-values obtained from independent logistic models.
bP-value obtained from a single logistic model including the interaction term.
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British Journal of Cancer (2003) 88(1), 96–101 & 2003 Cancer Research UKterone-receptor-negative tumours (ER+PR ) in association with
uPA–PAI-1 complexes, there appears no increased incidence of
nodal invasion. Thus, in the above-mentioned case of tumours
with both oestrogen and progesterone receptor expression, the
significant increase of nodal metastasis related to uPA–PAI-1
complexes seems to be associated with progesterone-receptor
positivity only. While the number of ER+PR  tumours giving rise
to this hypothesis was comparatively small (19 out of 189), the OR
associated with uPA–PAI-1 was remarkably similar to the one
observed among patients without hormonal receptors and neither
of them was close to being statistically significant.
Multivariate analysis
According to the above-mentioned results, the subsequent multi-
variate analysis was carried out including an interaction term
between PR and uPA–PAI-1 complexes. While this term was
statistically significant (P¼0.032), the main effect for uPA–PAI
complexes was very close to 1 (OR¼0.98). Thus, we readapted the
model considering the uPA–PAI-1 effect only inside the group of
PR-positive tumours. These results are presented in Table 3.
The final multivariate model (Table 3) confirmed the indepen-
dent prognostic strength of CD44 and suggests an important role
for tumour size and histologic grade, even though these two
variables failed to attain statistical significance. The protective role
for hormonal receptors seemed to be restricted to the presence of
both ER and PR. However, uPA–PAI-1 complexes reversed this
protective effect, producing an almost four-fold increase of risk.
Finally, when the multivariate model was applied maintaining
the stratification by progesterone receptor expression (Table 4),
the prognostic value for predicting axillary invasion of tumour
size, histologic grade, CD44std-negativity and uPA–PAI-1 com-
plex accumulation was only observed in progesterone-receptor-
positive tumours, whereas for their progesterone-receptor-nega-
tive counterparts, the only independent predictor was CD44std. In
this group, a Ki67-labelling index 410% was also associated with
an almost significantly increased risk.
DISCUSSION
Pedersen et al (2000) have studied uPA–PAI-1 complex levels in
breast cancer patients using a different method from the one
employed by us. Their results and ours are also not strictly
comparable in that we studied only early-stage unifocal cancers of
less than 2cm diameter, whereas they included into their study all
stages of the disease. Pedersen et al measured the uPA–PAI-1
fraction biochemically in tumour tissue extracts, and correlated
the obtained results both with the incidence of nodal inavsion and
with survival. They found that a high uPA–PAI-1 complex fraction
was associated with a longer survival and a lower incidence of
axillary nodal invasion. However, these relations lost statistical
significance in their multivariate analysis, in favour of total PAI-1
levels and lymph node status. The apparent discrepancy between
our results and those reported by Pedersen et al may be
attributable to the difference in the tumours studied: whereas, as
has been said, we restricted our analysis to early, T1 breast cancers,
they included all stages into their analysis. As can be seen from
their univariate analysis, they found a highly significant
(Po0.0001) association between uPA–PAI-1 complexes and a
tumour size of 2cm or less. This may in itself explain the
significant association found in their univariate analysis with a
better survival and lower incidence of axillary metastasis (it may
also explain, incidentally, why the latter associations are lost in the
multivariate analysis). Even within our very selected group of
small tumours, we also found a trend towards an association of
uPA–PAI-1 complex expression and lower tumour size. In fact,
uPA–PAI-1 complexes were detected by us in 41 out of 53 (77.4%)
T1a, b tumours, with a diameter of 1cm or less vs 93 out of 136
(68.3%) T1c tumours, with a diameter between 1.1 and 2cm.
However, this difference did not attain statistical significance
(P¼0.29). In opposition to the findings of Pedersen et al, Sten-
Lindner et al (2001) have recently reported a significantly worse
relapse-free survival for patients with breast cancers showing
higher cytosol concentrations of uPA–PAI-1 complex. Our results
are more in agreement with these latter ones, since axillary nodal
invasion is directly related to survival.
Interestingly, we found in our series of early-stage breast cancers
that the association of uPA–PAI-1 complex and progesterone
receptor expression predicted a significantly higher incidence of
axillary node metastasis. This relation was maintained throughout
the whole statistical analysis, including the multivariate model,
where the odds ratio for axillary node invasion in tumours
expressing both uPA–PAI-1-complexes and progesterone recep-
tors was 13.79. Although the 95% confidence interval for this odds
ratio is very large (1.95–97.4), it is placed far to the right of the
null line, and thus statistically significant, in contrast with the
results obtained for the group of tumours not expressing
progesterone receptors (Table 4). Although the statistical evidence
is solid, our results must still be interpreted with a certain degree
of caution. In fact, unlike clinical drug trials, where protocols
prespecify which analyses should be carried out, and which
should be considered primary and secondary, a study such as ours,
where the prognostic power of a given biological marker is
investigated for the first time, is much less rigid in this sense. A
number of interactions are tested in a logistic regression model,
and if an interesting one is found, it is followed through to the end,
such as we have done. In this context, there is still a small chance
for serendipity, which must always be considered. Nevertheless,
and with these limitations in mind, we still believe that the
results are solid, since the interaction of progesterone receptor-
and uPA–PAI-complex-positivity has been tested from every
possible angle, and, as Table 4 clearly shows, there seem to exist
huge biological differences in relation to the expression or
not of progesterone receptors by the tumours, especially in
association with the expression of uPA–PAI complexes by
them.
Table 3 Prognostic factors related to axillary node invasion in early (T1)
breast cancer: multivariate analysis including the interaction between uPA–
PAI and positive progesterone receptors (PR+)
OR 95% CI P-value
Tumour size
>1cm 1
p1cm 0.34 0.12–1.00 0.051
Hormone receptors and uPA–PAI
a
ER  and PR  1 0.20–4.66 0.955
ER+ and PR  0.96 0.04–2.29 0.199
ER+ and PR+, and uPA–PAI negative
a 0.31 1.28–11.6 0.017
ER+ and PR+, and uPA–PAI positive
a 3.85
Histologic grade
1–2 1
3 2.56 0.90–7.27 0.077
Ki67
p10% 1
>10% 2.09 0.76–5.75 0.154
CD44
Positive 1
Negative 6.86 2.69–17.5 o0.001
aThe interaction term PR and uPA–PAI was statistically significant (P=0.032), but
uPA–PAI complexes only showed any effect in PR+ tumours. The model was
therefore adapted to consider this variable only among PR+ cases (see text).
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British Journal of Cancer (2003) 88(1), 96–101 & 2003 Cancer Research UKHormone receptor expression is generally considered a biolo-
gical feature of good prognosis in breast cancer. Why progesterone
receptor expression, when associated with uPA–PAI-1 complex
expression, might favour axillary metastasis is therefore puzzling
at first sight. However, recent studies performed on endometrial
stromal cells have shown that epithelial growth factor (EGF)
expression and progesterone receptor expression are both
necessary for maximal PAI-1 expression (Lockwood, 2001). PAI-
1, besides uPA inactivation, has been shown to have other
paradoxical roles, which may explain why PAI-1 levels are one of
the most powerful ominous prognostic factors in breast cancer. So,
Chazaud et al (2002) have shown PAI-1 to induce the formation of
filopodia and to facilitate the migration of breast cancer cells,
suggesting a chemokine-like, metastasis-enhancing role for PAI-1.
Furthermore, they found that, in order to exert this promigratory
effect, the uPAR–uPA–PAI-1 system must be functioning in all its
parts, including the last step, which involves the internalisation of
uPA–PAI-1 complexes by means of endocytosis, mediated by the
low-density lipoprotein receptor-related protein (LRP). In our
study, we have detected the final link of the chain, that is, the
presence of uPA–PAI-1 complexes inside the tumour cell.
According to the just cited study by Chazaud et al, this implies
that all previous steps have taken place, including PAI-1
expression, which, according to Lockwood et al, is directly related
to progesterone receptor expression. Pedersen et al (2000) and
Sten-Lindner et al (2001), finally, have convincingly shown that the
uPA–PAI-1-complex fraction is directly related to the amount of
total PAI-1.
All these findings taken together seem to indicate that our
tumours expressing both uPA–PAI-1 complexes and progesterone
receptors are probably the ones also expressing the highest levels
of PAI-1, with its inherent bad prognosis, and also showing the
highest activity of the uPAR–uPA–PAI-1 system, with its
promigratory, metastasis-enhancing effect on breast cancer cells.
In conclusion, the detection of uPA–PAI-1 complexes inside the
tumour cells in early (T1) breast cancers expressing progesterone
receptors is associated with a significantly higher incidence of
axillary metastasis, and this might be of clinical value at the
present time, where there exists an increasing trend towards
avoiding axillary dissection at all in the presence of very small
breast cancers with clinically negative axillae.
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